Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Jenkins

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Respiratory Research|March 14, 2020
Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trialsJinping Zheng, Jin-Fu Xu, Martin Jenkins, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|April 9, 2005
The Living Planet Index: using species population time series to track trends in biodiversityJonathan Loh, Rhys E Green, Taylor Ricketts, et al.
Rheumatology (Oxford, England)|April 6, 2016
Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritisIris M Markusse, Robert Landewé, Ron Wolterbeek, et al.
Therapeutic Advances in Respiratory Disease|December 24, 2019
Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β<sub>2</sub>-agonist fixed-dose combinations in COPDMohd Kashif Siddiqui, Pragya Shukla, Martin Jenkins, et al.
Respiratory Research|October 8, 2021
A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary diseaseOmar Usmani, Nicolas Roche, Ezanul Wahab, et al.
Respiratory Medicine|May 5, 2022
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS studyDave Singh, Klaus F Rabe, Fernando J Martinez, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 17, 2020
Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment ComparisonsJohn R Hurst, Kevin Gruffydd-Jones, Mousumi Biswas, et al.
Therapeutic Advances in Respiratory Disease|August 25, 2021
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trialKlaus F Rabe, Fernando J Martinez, Dave Singh, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 6, 2020
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE StudiesFernando J Martinez, Klaus F Rabe, Brian J Lipworth, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Adaptive Design: Results of 2012 Survey on Perception and UseCaroline Claire Morgan, Susan Huyck, Martin Jenkins, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Respiratory Research|March 14, 2020
Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trialsJinping Zheng, Jin-Fu Xu, Martin Jenkins, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|April 9, 2005
The Living Planet Index: using species population time series to track trends in biodiversityJonathan Loh, Rhys E Green, Taylor Ricketts, et al.
Rheumatology (Oxford, England)|April 6, 2016
Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritisIris M Markusse, Robert Landewé, Ron Wolterbeek, et al.
Therapeutic Advances in Respiratory Disease|December 24, 2019
Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β<sub>2</sub>-agonist fixed-dose combinations in COPDMohd Kashif Siddiqui, Pragya Shukla, Martin Jenkins, et al.
Respiratory Research|October 8, 2021
A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary diseaseOmar Usmani, Nicolas Roche, Ezanul Wahab, et al.
Respiratory Medicine|May 5, 2022
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS studyDave Singh, Klaus F Rabe, Fernando J Martinez, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 17, 2020
Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment ComparisonsJohn R Hurst, Kevin Gruffydd-Jones, Mousumi Biswas, et al.
Therapeutic Advances in Respiratory Disease|August 25, 2021
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trialKlaus F Rabe, Fernando J Martinez, Dave Singh, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 6, 2020
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE StudiesFernando J Martinez, Klaus F Rabe, Brian J Lipworth, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Adaptive Design: Results of 2012 Survey on Perception and UseCaroline Claire Morgan, Susan Huyck, Martin Jenkins, et al.
Pageof 4